High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease

Jens Kastrup, Julia S Johansen, Per Winkel, Jørgen Fischer Hansen, Per Hildebrandt, Gorm Boje Jensen, Christian M Jespersen, Erik Kjøller, Hans Jørn Kolmos, Inga Lind, Henrik Nielsen, Christian Gluud, CLARICOR Trial Group

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Udgivelsesdato: 2009-Mar-6
OriginalsprogEngelsk
TidsskriftEuropean Heart Journal
Vol/bind30
Udgave nummer9
Sider (fra-til)1066-72
Antal sider7
ISSN0195-668X
DOI
StatusUdgivet - 6. mar. 2009

Fingeraftryk

Coronary Artery Disease
Serum
Confidence Intervals
Atherosclerotic Plaques
Diabetes Mellitus
Smoking
Macrophages

Citer dette

Kastrup, Jens ; Johansen, Julia S ; Winkel, Per ; Hansen, Jørgen Fischer ; Hildebrandt, Per ; Jensen, Gorm Boje ; Jespersen, Christian M ; Kjøller, Erik ; Kolmos, Hans Jørn ; Lind, Inga ; Nielsen, Henrik ; Gluud, Christian ; Trial Group, CLARICOR. / High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. I: European Heart Journal. 2009 ; Bind 30, Nr. 9. s. 1066-72.
@article{6c47220012e711deb27a000ea68e967b,
title = "High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease",
abstract = "Aims Macrophages in atherosclerotic plaques secrete YKL-40. We tested the hypothesis if high serum YKL-40 concentration predicts coronary events and death of patients with stable coronary artery disease (CAD). Methods and results During the 2.6 years follow-up period (median 2.77 year, interquartile range 0.23 year), 270 patients among the 4298 patients with stable CAD in the CLARICOR trial suffered myocardial infarction (MI) and 377 died (187 classified as cardiovascular death). Serum YKL-40 transformed as Y=log[max(82, serum YKL-40/microg/L)] was significantly associated with cardiovascular death [hazard ratio (HR) = 1.88, 95{\%} confidence interval (CI) = 1.54-2.31, P < 0.001], all-cause mortality (HR = 2.01, 95{\%} CI = 1.75-2.31, P < 0.001), and MI (HR = 1.38, 95{\%} CI = 1.13-1.68, P = 0.002). Following multivariable adjustment for cardiovascular risk factors (age, sex, previous MI, smoking status, hypertension, diabetes mellitus) and selected medical treatments Y contributed significantly to prediction of all-cause mortality (P < 0.001) and cardiovascular mortality (P = 0.001), but not MI (P = 0.25). Conclusion High serum YKL-40 is associated with MI, cardiovascular and all-cause mortality in patients with stable CAD.",
author = "Jens Kastrup and Johansen, {Julia S} and Per Winkel and Hansen, {J{\o}rgen Fischer} and Per Hildebrandt and Jensen, {Gorm Boje} and Jespersen, {Christian M} and Erik Kj{\o}ller and Kolmos, {Hans J{\o}rn} and Inga Lind and Henrik Nielsen and Christian Gluud and {Trial Group}, CLARICOR",
year = "2009",
month = "3",
day = "6",
doi = "10.1093/eurheartj/ehp049",
language = "English",
volume = "30",
pages = "1066--72",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Heinemann",
number = "9",

}

Kastrup, J, Johansen, JS, Winkel, P, Hansen, JF, Hildebrandt, P, Jensen, GB, Jespersen, CM, Kjøller, E, Kolmos, HJ, Lind, I, Nielsen, H, Gluud, C & Trial Group, CLARICOR 2009, 'High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease', European Heart Journal, bind 30, nr. 9, s. 1066-72. https://doi.org/10.1093/eurheartj/ehp049

High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. / Kastrup, Jens; Johansen, Julia S; Winkel, Per; Hansen, Jørgen Fischer; Hildebrandt, Per; Jensen, Gorm Boje; Jespersen, Christian M; Kjøller, Erik; Kolmos, Hans Jørn; Lind, Inga; Nielsen, Henrik; Gluud, Christian; Trial Group, CLARICOR.

I: European Heart Journal, Bind 30, Nr. 9, 06.03.2009, s. 1066-72.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease

AU - Kastrup, Jens

AU - Johansen, Julia S

AU - Winkel, Per

AU - Hansen, Jørgen Fischer

AU - Hildebrandt, Per

AU - Jensen, Gorm Boje

AU - Jespersen, Christian M

AU - Kjøller, Erik

AU - Kolmos, Hans Jørn

AU - Lind, Inga

AU - Nielsen, Henrik

AU - Gluud, Christian

AU - Trial Group, CLARICOR

PY - 2009/3/6

Y1 - 2009/3/6

N2 - Aims Macrophages in atherosclerotic plaques secrete YKL-40. We tested the hypothesis if high serum YKL-40 concentration predicts coronary events and death of patients with stable coronary artery disease (CAD). Methods and results During the 2.6 years follow-up period (median 2.77 year, interquartile range 0.23 year), 270 patients among the 4298 patients with stable CAD in the CLARICOR trial suffered myocardial infarction (MI) and 377 died (187 classified as cardiovascular death). Serum YKL-40 transformed as Y=log[max(82, serum YKL-40/microg/L)] was significantly associated with cardiovascular death [hazard ratio (HR) = 1.88, 95% confidence interval (CI) = 1.54-2.31, P < 0.001], all-cause mortality (HR = 2.01, 95% CI = 1.75-2.31, P < 0.001), and MI (HR = 1.38, 95% CI = 1.13-1.68, P = 0.002). Following multivariable adjustment for cardiovascular risk factors (age, sex, previous MI, smoking status, hypertension, diabetes mellitus) and selected medical treatments Y contributed significantly to prediction of all-cause mortality (P < 0.001) and cardiovascular mortality (P = 0.001), but not MI (P = 0.25). Conclusion High serum YKL-40 is associated with MI, cardiovascular and all-cause mortality in patients with stable CAD.

AB - Aims Macrophages in atherosclerotic plaques secrete YKL-40. We tested the hypothesis if high serum YKL-40 concentration predicts coronary events and death of patients with stable coronary artery disease (CAD). Methods and results During the 2.6 years follow-up period (median 2.77 year, interquartile range 0.23 year), 270 patients among the 4298 patients with stable CAD in the CLARICOR trial suffered myocardial infarction (MI) and 377 died (187 classified as cardiovascular death). Serum YKL-40 transformed as Y=log[max(82, serum YKL-40/microg/L)] was significantly associated with cardiovascular death [hazard ratio (HR) = 1.88, 95% confidence interval (CI) = 1.54-2.31, P < 0.001], all-cause mortality (HR = 2.01, 95% CI = 1.75-2.31, P < 0.001), and MI (HR = 1.38, 95% CI = 1.13-1.68, P = 0.002). Following multivariable adjustment for cardiovascular risk factors (age, sex, previous MI, smoking status, hypertension, diabetes mellitus) and selected medical treatments Y contributed significantly to prediction of all-cause mortality (P < 0.001) and cardiovascular mortality (P = 0.001), but not MI (P = 0.25). Conclusion High serum YKL-40 is associated with MI, cardiovascular and all-cause mortality in patients with stable CAD.

U2 - 10.1093/eurheartj/ehp049

DO - 10.1093/eurheartj/ehp049

M3 - Journal article

VL - 30

SP - 1066

EP - 1072

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 9

ER -